139 related articles for article (PubMed ID: 28736187)
1. Protein biomarker for pancreatic ductal adenocarcinoma.
Burki T
Lancet Oncol; 2017 Sep; 18(9):e511. PubMed ID: 28736187
[No Abstract] [Full Text] [Related]
2. Protein-metabolite panel for early-stage pancreatic cancer.
Burki TK
Lancet Oncol; 2018 Oct; 19(10):e512. PubMed ID: 30146244
[No Abstract] [Full Text] [Related]
3. New Biomarker Identified for PDAC.
Cancer Discov; 2017 Sep; 7(9):OF3. PubMed ID: 28739842
[TBL] [Abstract][Full Text] [Related]
4. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma.
Byrling J; Hilmersson KS; Ansari D; Andersson R; Andersson B
Clin Transl Oncol; 2022 Feb; 24(2):297-304. PubMed ID: 34319497
[TBL] [Abstract][Full Text] [Related]
5. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
6. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
7. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
[TBL] [Abstract][Full Text] [Related]
8. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma.
Poruk KE; Firpo MA; Scaife CL; Adler DG; Emerson LL; Boucher KM; Mulvihill SJ
Pancreas; 2013 Mar; 42(2):193-7. PubMed ID: 23407481
[TBL] [Abstract][Full Text] [Related]
9. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
10. Survivin expression and serum levels in pancreatic cancer.
Dong H; Qian D; Wang Y; Meng L; Chen D; Ji X; Feng W
World J Surg Oncol; 2015 May; 13():189. PubMed ID: 26016480
[TBL] [Abstract][Full Text] [Related]
11. Hepatobiliary and Pancreatic: Pancreatic cancer with elevated serum IgG4 level due to multiple myeloma mimicking localized autoimmune pancreatitis.
Kato S; Kuwatani M; Kawakubo K; Sugiura R; Hirata K; Tanikawa S; Mitsuhashi T; Shiratori S; Sakamoto N
J Gastroenterol Hepatol; 2018 Jul; 33(7):1310. PubMed ID: 29761833
[No Abstract] [Full Text] [Related]
12. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
13. Exocrine-endocrine pancreatic cancer and alpha-fetoprotein.
Brandi G; Nobili E; Capizzi E; Corti B; Di Cicilia R; Di Marco M; Biasco G
Pancreas; 2008 Aug; 37(2):223-5. PubMed ID: 18665089
[No Abstract] [Full Text] [Related]
14. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
15. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer.
Ankeny JS; Court CM; Hou S; Li Q; Song M; Wu D; Chen JF; Lee T; Lin M; Sho S; Rochefort MM; Girgis MD; Yao J; Wainberg ZA; Muthusamy VR; Watson RR; Donahue TR; Hines OJ; Reber HA; Graeber TG; Tseng HR; Tomlinson JS
Br J Cancer; 2016 Jun; 114(12):1367-75. PubMed ID: 27300108
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-enabled blood tests for early detection of pancreatic ductal adenocarcinoma.
Caputo D; Caracciolo G
Cancer Lett; 2020 Feb; 470():191-196. PubMed ID: 31783084
[TBL] [Abstract][Full Text] [Related]
18. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
19. MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.
Gayral M; Jo S; Hanoun N; Vignolle-Vidoni A; Lulka H; Delpu Y; Meulle A; Dufresne M; Humeau M; Chalret du Rieu M; Bournet B; Sèlves J; Guimbaud R; Carrère N; Buscail L; Torrisani J; Cordelier P
World J Gastroenterol; 2014 Aug; 20(32):11199-209. PubMed ID: 25170204
[TBL] [Abstract][Full Text] [Related]
20. Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.
Lee JS; Park SS; Lee YK; Norton JA; Jeffrey SS
Mol Oncol; 2019 Aug; 13(8):1623-1650. PubMed ID: 31243883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
